Cancer drug Imatinib's Long-Term safety tracked in ongoing patients

NCT ID NCT01742299

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at the long-term safety of imatinib, a daily pill for certain cancers like GIST and CML. It includes 250 patients who were already benefiting from imatinib in a previous Novartis trial and continue taking it. The main goal is to track side effects over time, with no new treatment being tested.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

imatinib (a targeted cancer drug taken as a daily pill)

What this could lead to

If successful, this study will confirm that long-term imatinib use is safe and continues to control GIST or CML, supporting its ongoing use.

What could go wrong

This is a roll-over safety study, not a test of new effectiveness. It only includes patients already benefiting, so results may not apply to all. Side effects remain possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic myelogenous leukemia, BCR-ABL1 positive gastrointestinal stromal tumor Leukemia, Myelogenous, Chronic, BCR-ABL Positive

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GIST AND CML

Contacts and locations

Show contact details

Locations

Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Northwestern University

Chicago, Illinois, 60611, United States
Novartis Investigative Site

Nanjing, Jiangsu, 210002, China
Novartis Investigative Site

Beijing, 100036, China
Novartis Investigative Site

Beijing, 100730, China
Novartis Investigative Site

Guangzhou, 510060, China
Novartis Investigative Site

Shanghai, 200433, China
Novartis Investigative Site

Helsinki, FIN-00029, Finland
Novartis Investigative Site

Lille, 59037, France
Novartis Investigative Site

Pessac, 33604, France
Novartis Investigative Site

Poitiers, 86021, France
Novartis Investigative Site

Hong Kong, 999077, Hong Kong
Novartis Investigative Site

Cluj-Napoca, Cluj, 400015, Romania
Novartis Investigative Site

Bucharest, 022328, Romania
Novartis Investigative Site

Singapore, 119228, Singapore
Novartis Investigative Site

Singapore, 168583, Singapore
Novartis Investigative Site

Singapore, 169608, Singapore
Novartis Investigative Site

Basel, 4031, Switzerland
Novartis Investigative Site

Bangkok, 10700, Thailand
Novartis Investigative Site

Ankara, Sihhiye-Altindag, 06230, Turkey (Türkiye)
Novartis Investigative Site

Sutton, Surrey, SM2 5PT, United Kingdom
Novartis Investigative Site

Manchester, M20 2BX, United Kingdom
Oregon Health Sciences University

Portland, Oregon, 97239, United States
Sidney Kimmel CCC At JH

Baltimore, Maryland, 21231, United States
Uni Of TX MD Anderson Cancer Cntr

Houston, Texas, 77030, United States
University of California LA

Los Angeles, California, 90095, United States
Weill Cornell Medical Center

New York, New York, 10021, United States